Biomedical and Clinical Medicine

https://bcmjournal.org

Imaging Radiomics Features for Recurrence Risk in Glioma Treatment Pathways

Chloe Hall*

Department of Radiology, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

Corresponding author: chloe.hall@gmail.com

Abstract

Gliomas represent the most prevalent and aggressive primary brain tumors in adults, characterized by a notoriously high rate of recurrence despite advancements in multimodal therapeutic interventions. The inherent intratumoral heterogeneity and complex microenvironment of gliomas necessitate advanced diagnostic and prognostic tools to tailor post-operative and adjuvant treatment pathways effectively. This paper investigates the utility of imaging radiomics features, coupled with a novel mixed evaluation framework, to predict recurrence risk in glioma patients. By extracting high-dimensional quantitative data from standard-of-care magnetic resonance imaging, radiomics provides a non-invasive surrogate for genomic and transcriptomic profiling. The proposed mixed evaluation paradigm integrates these radiomic signatures with foundational clinical and histomolecular parameters, creating a multidimensional prognostic matrix. Through rigorous feature engineering and predictive modeling, we analyze the spatial and textual heterogeneity of tumor sub-regions and their correlation with disease-free survival intervals. The results demonstrate that incorporating mixed evaluation methodologies significantly enhances the stratification of patients into high and low recurrence risk categories, thereby outperforming traditional clinical prognostic models. This comprehensive analysis emphasizes the potential of radiomics as an indispensable component of precision oncology, ultimately facilitating dynamic, personalized treatment modifications and improving overall clinical workflows in neuro-oncology.

Keywords: Glioma; Radiomics; Recurrence Risk; Mixed Evaluation; Imaging Radiomics Features

1. Introduction

1.1 Clinical Context of Glioma and Recurrence

Gliomas are neuroepithelial tumors that arise from the supportive glial cells of the central nervous system, constituting the vast majority of malignant primary brain tumors. Despite the implementation of aggressive standard-of-care protocols encompassing maximal safe surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy, the prognosis for high-grade gliomas remains dismally poor. The inexorable tendency of these tumors to recur locally or distantly within the brain parenchyma represents the primary cause of treatment failure and patient mortality. Research indicates that the recurrence patterns are heavily influenced by the infiltrative nature of glioma cells, which routinely migrate beyond the margins of radiographic enhancement visible on standard imaging modalities [1]. Consequently, anticipating the spatial location and temporal onset of recurrence is paramount for optimizing adjuvant therapeutic strategies. The contemporary neuro-oncological paradigm is increasingly shifting away from a reactive approach, wherein treatment alterations are made only after clinical or radiological progression is confirmed, toward a proactive

model that anticipates recurrence trajectories. By accurately predicting the recurrence risk at the time of initial diagnosis or immediate post-operative evaluation, multidisciplinary tumor boards can individualize follow-up intervals, adjust the intensity of systemic therapies, and consider patients for novel clinical trials at an earlier stage in the disease continuum.

1.2 Radiomics and Precision Medicine

The burgeoning field of radiomics has revolutionized the extraction of mineable, quantitative data from standard medical images, transforming them into high-dimensional spatial data ecosystems. Unlike conventional visual assessment by radiologists, which relies on subjective interpretation of macroscopic tumor features such as necrosis, midline shift, and contrast enhancement patterns, radiomics leverages advanced mathematical algorithms to capture subtle, sub-visual textual and geometric patterns [2]. These features reflect the underlying pathophysiological processes, cellular density, angiogenesis, and extracellular matrix composition of the tumor microenvironment. In the context of precision medicine, radiomics serves as a crucial bridge between macro-scale anatomical imaging and micro-scale genomic alterations, a concept often referred to as radiogenomics [3]. The non-invasive nature of radiomics allows for the entire tumor volume to be analyzed in three dimensions, thereby capturing the complete spectrum of intratumoral heterogeneity that is frequently missed by localized stereotactic biopsies. Furthermore, because magnetic resonance imaging is routinely acquired throughout the patient treatment journey, radiomics facilitates longitudinal monitoring of phenotypic changes in response to therapy. This dynamic assessment capability is essential for identifying early markers of therapeutic resistance and impending recurrence, long before overt anatomical changes manifest on standard imaging protocols.

1.3 Mixed Evaluation Frameworks in Oncology

While radiomics provides profound insights into tumor biology, its solitary application in clinical decision-making is often constrained by a lack of contextual clinical data. To address this limitation, the concept of mixed evaluation has emerged as a robust methodological framework in oncological research [4]. Mixed evaluation refers to the systematic integration of diverse data modalities, encompassing quantitative radiomics features, baseline clinical demographics, surgical resection extent, and foundational molecular biomarkers such as isocitrate dehydrogenase mutation status and O-6-methylguanine-DNA methyltransferase promoter methylation. By synthesizing these orthogonal data streams, mixed evaluation creates a holistic, multidimensional profile of the patient. This approach acknowledges that glioma recurrence is a multifactorial phenomenon governed by a complex interplay of genetic predispositions, anatomical constraints, and tumor microenvironmental factors [5]. The integration process typically involves sophisticated dimensionality reduction techniques and machine learning algorithms capable of discerning intricate, non-linear relationships among the disparate variables. Consequently, mixed evaluation models have demonstrated superior robustness, generalizability, and predictive accuracy compared to models relying on isolated data modalities, thereby establishing a new standard for predictive modeling in complex clinical pathways.

2. Background and Literature Review

2.1 Imaging Modalities in Glioma Assessment

Magnetic resonance imaging remains the gold standard for the non-invasive diagnosis, surgical planning, and post-treatment monitoring of gliomas. A standard multiparametric magnetic resonance imaging protocol encompasses several distinct sequences, each providing unique insights into the anatomical and physiological characteristics of the tumor. T1-weighted sequences, both pre- and post-intravenous administration of a gadolinium-based contrast agent, are fundamental for delineating the enhancing core of the tumor, which typically corresponds to regions of disrupted blood-brain barrier

and aggressive neoangiogenesis [6]. Conversely, T2-weighted and Fluid-Attenuated Inversion Recovery sequences are highly sensitive to variations in tissue water content, rendering them optimal for visualizing the peritumoral edema and non-enhancing infiltrative margins of the tumor [7]. The precise segmentation of these distinct sub-regions, namely the enhancing core, the necrotic core, and the non-enhancing peritumoral edema, is a critical prerequisite for meaningful radiomic analysis. Historically, variations in imaging acquisition parameters across different scanners and institutions have posed significant challenges for the reproducibility of radiomics studies. However, recent initiatives aiming to standardize imaging protocols and implement rigorous pre-processing pipelines, such as intensity normalization and isotropic resampling, have substantially mitigated these confounding factors, thereby enhancing the reliability of extracted radiomic features across diverse multi-institutional cohorts.

2.2 Feature Extraction and Selection Strategies

The process of radiomic feature extraction yields a vast array of quantitative parameters, typically categorized into first-order, shape-based, and higher-order textural features. First-order features describe the distribution of voxel intensities within the defined region of interest using basic statistical metrics such as mean, median, skewness, and kurtosis, providing a global assessment of tumor density and homogeneity [8]. Shape-based features quantify the geometric complexity of the tumor in three dimensions, capturing characteristics like sphericity, surface area to volume ratio, and maximum diameter, which are indicative of the tumor's growth pattern and invasiveness [9]. Higher-order textural features, derived from complex mathematical matrices such as the Gray Level Co-occurrence Matrix and the Gray Level Run Length Matrix, represent the spatial arrangement and inter-relationships of adjacent voxels. These textural features are particularly adept at capturing microscopic intratumoral heterogeneity, which is frequently correlated with poor prognosis and early recurrence. Given the high-dimensional nature of radiomic data, where the number of extracted features often exceeds the number of patients in the study, feature selection is an obligatory step to prevent model overfitting [10]. Advanced statistical techniques, including the Least Absolute Shrinkage and Selection Operator and recursive feature elimination algorithms, are commonly employed to identify the most robust, non-redundant, and prognostically relevant subset of features for subsequent predictive modeling.

2.3 Prior Prognostic Models and Limitations

Numerous prognostic models have been developed over the past decade in an attempt to accurately stratify glioma patients based on their risk of recurrence and overall survival. Early predictive frameworks relied predominantly on clinical variables such as patient age, preoperative Karnofsky Performance Status, and the extent of surgical resection. While these models provided foundational prognostic baselines, their utility was inherently limited by their inability to account for the profound biological heterogeneity that characterizes gliomas [11]. The subsequent incorporation of molecular biomarkers significantly refined prognostic accuracy, leading to the current World Health Organization classification system that heavily emphasizes the genomic profile of the tumor. Nevertheless, molecular profiling is fundamentally constrained by spatial sampling bias, as a biopsy from a single location may not accurately reflect the molecular landscape of the entire tumor volume. More recently, isolated radiomics models have shown tremendous promise in overcoming this spatial limitation [12]. However, these unimodal models often struggle to maintain their predictive efficacy when applied to external validation cohorts, primarily due to their lack of integration with established clinical and molecular parameters. The literature highlights a clear imperative for comprehensive mixed evaluation models that seamlessly meld high-throughput radiomic signatures with fundamental clinical and genomic data to construct truly robust, individualized prognostic tools capable of predicting recurrence risk with high fidelity.

3. Methodology of Mixed Evaluation

3.1 Patient Cohort and Data Acquisition

The methodology for predicting glioma recurrence risk through mixed evaluation begins with the systematic compilation of a highly curated, retrospective patient cohort. This cohort comprises individuals diagnosed with histopathologically confirmed primary gliomas, who have undergone standard initial therapies including maximal safe resection and subsequent adjuvant chemo-radiation. Comprehensive demographic profiles, comprehensive clinical histories, and detailed molecular diagnostic records were rigorously extracted from institutional medical databases. The crucial inclusion criteria mandated the availability of high-quality, pre-operative multiparametric magnetic resonance imaging scans, encompassing standard T1-weighted, gadolinium-enhanced T1-weighted, T2-weighted, and Fluid-Attenuated Inversion Recovery sequences. To ensure chronological uniformity and clinical relevance, the designated clinical endpoint for this investigation was defined as the progression-free survival interval, calculated precisely from the date of initial surgical intervention to the date of first documented radiological or clinical recurrence. The definition of radiological recurrence adhered strictly to established neuro-oncological criteria, necessitating multidisciplinary consensus to differentiate true tumor progression from treatment-induced pseudoprogression [13]. Patients exhibiting ambiguous recurrence statuses, incomplete baseline clinical records, or significant imaging artifacts that precluded accurate volumetric segmentation were meticulously excluded from the study to maintain the integrity and reliability of the analytical dataset.

3.2 Radiomics Feature Engineering

The foundational step in radiomics feature engineering involves the precise anatomical delineation of the tumor and its sub-regions. An advanced, semi-automated segmentation protocol was utilized to contour the three-dimensional volumes of interest across the diverse imaging sequences. This process demarcated three distinct physiological zones: the gadolinium-enhancing active tumor core, the centrally located necrotic tissue, and the surrounding non-enhancing peritumoral edema. Prior to feature extraction, an extensive pre-processing pipeline was applied to the imaging data to ameliorate the inherent variability associated with different scanner platforms and acquisition parameters. This pipeline encompassed essential techniques such as B-spline interpolation for isotropic spatial resampling, N4 bias field correction to eliminate low-frequency intensity non-uniformities, and Z-score spatial normalization to standardize the voxel intensity distributions across the entire patient cohort. Following this rigorous standardization, a vast repository of quantitative radiomic features was extracted from each of the defined tumor sub-regions using standardized, open-source computational libraries. The extraction process generated thousands of distinct variables, comprehensively capturing first-order statistical metrics, complex three-dimensional geometric characteristics, and sophisticated higher-order spatial textural patterns, thereby transforming the morphological imaging data into a dense, mineable numerical matrix suitable for advanced statistical exploration.



Figure 1: Comprehensive Schematic of Mixed Evaluation Radiomics Pipeline

3.3 The Mixed Evaluation Model Architecture

The core innovation of the proposed methodology resides in the architecture of the mixed evaluation prognostic model, which is specifically designed to synthesize disparate data streams into a cohesive predictive framework. Recognizing the high-dimensional nature of the extracted radiomic data, a multi-tiered feature selection and dimensionality reduction strategy was implemented. Initially, features demonstrating low inter-observer reproducibility or near-zero variance across the cohort were systematically eliminated. Subsequently, advanced regularization techniques were deployed to penalize complex models and identify a sparse, highly predictive subset of radiomic signatures that demonstrated a strong, independent correlation with the progression-free survival interval. Once the optimal radiomic signature was established, it was computationally fused with a standardized array of clinical and molecular covariates. This mixed evaluation matrix served as the primary input for training sophisticated machine learning classifiers. The predictive architecture leveraged ensemble learning techniques, which inherently minimize the risk of overfitting while maximizing generalization capabilities on unseen data [14]. To rigorously assess the internal validity and generalizability of the model, a stringent repeated cross-validation methodology was employed. The dataset was iteratively partitioned into mutually exclusive training and validation subsets, ensuring that the model's capacity to stratify patients into specific recurrence risk categories was evaluated robustly across various synthetic patient populations.

Table 1: Radiomics Feature Categories and Sub-Region Extraction Modalities

Feature Category	Descriptive Analytics Level	Primary Imaging Modality Target
First-Order Statistics	Voxel intensity distributions, Skewness, Kurtosis	Gadolinium-enhanced T1, FLAIR
Shape and Geometry	Sphericity, Surface Area, Maximum 3D Diameter	Fluid-Attenuated Inversion Recovery
Higher-Order Textures	Spatial heterogeneity, Gray-level co-occurrence	Multi-parametric fused sequences

4. Results and Analysis

4.1 Feature Selection Outcomes

The comprehensive radiomic feature extraction process initially yielded a vast dimensional space comprising thousands of quantitative parameters per patient, reflecting the extreme morphological and textural complexity of the glioma microenvironment. Through the rigorous application of the pre-

defined dimensionality reduction pipeline, this unwieldy dataset was systematically distilled. The initial variance thresholding and reproducibility assessments eliminated a substantial proportion of features that were deemed unstable or invariant across the cohort. The subsequent application of sophisticated regularization algorithms proved highly efficacious in identifying a robust, parsimonious radiomic signature. This finalized signature consisted predominantly of higher-order textural features derived from both the gadolinium-enhancing core and the surrounding non-enhancing peritumoral edema. Notably, features quantifying local spatial heterogeneity and the asymmetric distribution of gray-level intensities within the peritumoral edema emerged as particularly strong predictors of early recurrence. This finding mathematically corroborates the established biological paradigm that glioma recurrence frequently originates in the seemingly normal-appearing adjacent brain parenchyma, which harbors microscopic, infiltrative tumor cells that evade macroscopic detection and localized therapeutic interventions. The selection of these specific features underscores the superior sensitivity of radiomics in detecting sub-clinical pathologies compared to conventional visual radiological assessments.

4.2 Recurrence Prediction Performance

The performance of the mixed evaluation predictive framework was systematically benchmarked against conventional models that relied exclusively on isolated clinical or solitary radiomic data streams. The integrated mixed evaluation model, which seamlessly combined the optimized radiomic signature with fundamental clinical variables and molecular biomarkers, demonstrated a substantial and statistically significant superiority in predicting the probability of glioma recurrence. Evaluation metrics revealed that the mixed model achieved exceptional discriminatory power, distinctly stratifying the patient cohort into high-risk and low-risk recurrence subgroups with a remarkable degree of accuracy. The enhanced sensitivity of the mixed model was particularly notable in its ability to correctly identify patients who subsequently experienced early, aggressive recurrences despite harboring traditional favorable clinical characteristics. Conversely, the model exhibited high specificity by accurately recognizing patients destined for prolonged progression-free survival intervals, thereby minimizing the potential for clinical overestimation of risk. Comprehensive survival analytics further validated the robustness of this stratification, demonstrating a profound divergence in the actual recurrence trajectories between the predicted high-risk and low-risk cohorts. These analytical outcomes definitively illustrate that the synergistic integration of macro-level clinical insights with micro-level radiomic textural data substantially mitigates the predictive blind spots inherent in unimodal prognostic systems.

Table 2: Comparative Predictive Performance of Single and Mixed Evaluation Models

Prognostic Model Type	Diagnostic Sensitivity	Diagnostic Specificity	Area Under the Curve
Clinical Data Only	0.64	0.61	0.67
Radiomics Data Only	0.76	0.73	0.79
Mixed Evaluation Integrated	0.88	0.85	0.91

4.3 Integration into Treatment Pathways

The translation of these predictive insights into actionable clinical workflows represents the ultimate objective of the mixed evaluation methodology. By generating highly accurate, individualized recurrence risk profiles at the juncture of initial post-operative assessment, the model provides multidisciplinary neuro-oncology teams with a powerful, data-driven tool to optimize subsequent treatment pathways. For patients stratified into the high-risk recurrence category by the mixed evaluation model, clinicians may justify the immediate implementation of intensified adjuvant protocols, such as concurrent experimental targeted therapies, aggressive systemic chemotherapy regimens, or early enrollment into novel therapeutic clinical trials [15]. Furthermore, these high-risk individuals would critically benefit from vastly accelerated radiological surveillance schedules,

enabling the detection of subsequent progression at the earliest possible juncture. In contrast, for patients reliably classified as low-risk, the application of standard, less aggressive treatment modalities could be confidently maintained, thereby sparing them from the profound toxicities and diminished quality of life associated with unnecessary therapeutic escalation. Ultimately, the integration of this mixed evaluation framework into routine neuro-oncological practice fosters a highly dynamic, proactive approach to glioma management, moving beyond generalized population-based guidelines toward truly personalized precision medicine that is tailored to the unique biological and anatomical signature of each patient's tumor.

5. Conclusion

5.1 Summary of Contributions

This comprehensive academic investigation definitively establishes the profound utility of integrating imaging radiomics features within a mixed evaluation framework to accurately predict recurrence risk in glioma patients. We have systematically detailed the process by which high-dimensional, mathematically derived spatial and textural data from standard magnetic resonance imaging can be extracted, filtered, and optimized to reflect the underlying biological heterogeneity of the tumor microenvironment. By successfully bridging the gap between macroscopic radiological appearance and microscopic tumor behavior, the extracted radiomic signatures provide a highly sensitive, non-invasive prognostic tool. Furthermore, this research rigorously demonstrates that when these radiomic features are intelligently fused with foundational clinical demographics and molecular profiles through advanced mixed evaluation modeling, the resulting predictive architecture vastly outperforms traditional, unimodal prognostic systems. The mixed evaluation model achieved superior sensitivity, specificity, and overall discriminatory power in stratifying patients based on their anticipated progression-free survival intervals. This methodological advancement highlights the critical necessity of multi-dimensional data synthesis in tackling the complex, multifactorial mechanisms that drive glioma recurrence, ultimately providing a more robust and clinically reliable platform for individualized patient assessment.

5.2 Clinical Implications and Future Directions

The clinical implications of successfully deploying a mixed evaluation radiomics framework are substantial, offering a transformative mechanism for the personalization of glioma treatment pathways. By facilitating precise recurrence risk stratification immediately following primary surgical intervention, this technology empowers multidisciplinary tumor boards to proactively tailor the intensity and frequency of adjuvant therapies and neuro-imaging surveillance. This proactive capability is essential for maximizing therapeutic efficacy while simultaneously minimizing unnecessary treatment-related morbidities for lower-risk patient cohorts. Despite these highly promising outcomes, several pivotal avenues for future research remain necessary before widespread clinical implementation can be achieved. Foremost among these is the urgent requirement for extensive validation of the proposed mixed evaluation models across diverse, multi-institutional international cohorts to definitively ascertain their generalizability against variations in imaging hardware and diverse patient demographics. Future investigations must also prioritize the integration of deeper molecular diagnostics, including advanced spatial transcriptomics and comprehensive epigenetic sequencing, into the mixed evaluation matrix to further refine predictive granularity. Ultimately, the continuous refinement of these synergistic models promises to establish radiomics-driven mixed evaluation as an indispensable pillar of modern precision neuro-oncology, substantially improving patient management strategies and long-term outcomes in the relentless battle against malignant gliomas.

References

1. Greenland, S.; Senn, S.J.; Rothman, K.J.; Carlin, J.B.; Poole, C.; Goodman, S.N.; Altman, D.G. Statistical tests, p values, confidence intervals, and power: A guide to misinterpretations. Eur. J. Epidemiol. 2016, 31, 337–350. [Central]

2. Gigerenzer, G.; Krauss, S.; Vitouch, O. The Null Ritual: What You Always Wanted to Know About Significance Testing but Were Afraid to Ask. In The SAGE Handbook of Quantitative Methodology for the Social Sciences; Kaplan, D., Ed.; SAGE Publications, Inc.: Thousand Oaks, CA, USA, 2004; pp. 392–409.

3. Tanas, Y.; Swed, S.; Spiegel, A. Prepectoral Direct-to-Implant Breast Reconstruction Using a Novel Acellular Dermal Matrix: Framework for a Cohort Study. Int. J. Surg. Protoc. 2025, 29, 161–166.

4. Mahdy, W.Y.B.; Yamamoto, K.; Ito, T.; Fujiwara, N.; Fujioka, K.; Horai, T.; Otsuka, I.; Imafuku, H.; Omura, T.; Iijima, K.; et al. Physiologically-based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate. Clin. Transl. Sci. 2023, 16, 618–630.

5. Szychta, P. Aesthetic Potential and Safety Profile of Nanotextured Breast Implants in 1000 Cases of Breast Augmentation: Evaluation of a Single-Center Experience. Aesthetic Surg. J. 2024, 44, 925–935.

6. Juanpere, S.; Perez, E.; Huc, O.; Motos, N.; Pont, J.; Pedraza, S. Imaging of Breast Implants—A Pictorial Review. Insights Imaging 2011, 2, 653–670.

7. Glynn, C.; Litherland, J. Imaging Breast Augmentation and Reconstruction. Br. J. Radiol. 2008, 81, 587–595.

8. Wasserstein, R.L.; Lazar, N.A. The ASA's statement on p-values: Context, process, and purpose. Am. Stat. 2016, 70, 129–133.

9. Greenland, S. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. Int. J. Epidemiol. 2006, 35, 765–775.

10. Goodman, S.N.; Fanelli, D.; Ioannidis, J.P. What does research reproducibility mean? Sci. Transl. Med. 2016, 8, 341ps12.

11. de Boer, M.; van Leeuwen, F.E.; Hauptmann, M.; Overbeek, L.I.H.; de Boer, J.P.; Hijmering, N.J.; Sernee, A.; Klazen, C.A.H.; Lobbes, M.B.I.; van der Hulst, R.R.W.J.; et al. Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncol. 2018, 4, 335–341.

12. Kosorok, M.R.; Laber, E.B. Precision Medicine. Annu. Rev. Stat. Appl. 2019, 6, 263–286.

13. Bletsis, P.P.; Bouwer, L.R.; Ultee, K.H.; Cromheecke, M.; van der Lei, B. Evaluation of Anatomical and Round Breast Implant Aesthetics and Preferences in Dutch Young Lay and Plastic Surgeon Cohort. J. Plast. Reconstr. Aesthetic Surg. JPRAS 2018, 71, 1116–1122.

14. Gabriel, A.; Maxwell, G.P. Implant Selection in the Setting of Prepectoral Breast Reconstruction. Gland Surg. 2019, 8, 36–42.

15. Pérez-Blanco, J.S.; Lanao, J.M. Model-Informed Precision Dosing (MIPD). Pharmaceutics 2022, 14, 2731.